B. Riley FBR analyst George Zavoico added Novavax to his firm's Alpha Generator list based on the upcoming top-line results of two key clinical trials expected in early Q1. If a Phase III trial of ResVax delivers positive results, Novavax will seek FDA approval in 2020, the analyst points out. Further, if a Phase II trial of NanoFlu delivers positive results, Novavax could commence pivotal Phase III trial in the second half of 2020, the analyst adds. These are multi-billion-dollar markets, and positive results could make Novavax an acquisition target by a major pharmaceutical company, Zavoico tells investors in a research note. He keeps a Buy rating on the shares with a $10 price target.

The World Health Organization's Technical Advisory Group on COVID-19 Vaccine Composition recommended the use of a monovalent JN.1 lineage COVID-19 vaccine as one approach to address the ongoing SARS-CoV-2 virus evolution, which is expected to lead to circulation of additional JN.1 descendant strains, Novavax stated. Novavax plans to be ready to deliver our JN.1 protein-based non-mRNA COVID-19 vaccine globally this fall. We have been developing and manufacturing this vaccine candidate at risk and are well positioned for the upcoming vaccination season, the company said. Reference Link